The metabolism of Zuclopenthixol can be decreased when combined with Betaxolol. Betaxolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine). The risk or severity of adverse effects can be increased when Betaxolol is combined with Carbachol. The risk or severity of adverse effects can be increased when Betaxolol is combined with Telmisartan. The metabolism of Granisetron can be decreased when combined with Betaxolol. Betaxolol may increase the hypotensive activities of Phentolamine. Droxicam may decrease the antihypertensive activities of Betaxolol. The risk or severity of adverse effects can be increased when Remifentanil is combined with Betaxolol. The risk or severity of adverse effects can be increased when Betaxolol is combined with Varenicline. The metabolism of Cyclobenzaprine can be decreased when combined with Betaxolol. Betaxolol may decrease the bronchodilatory activities of Orciprenaline. Piroxicam may decrease the antihypertensive activities of Betaxolol. Betaxolol may increase the hypotensive activities of Ambrisentan. The metabolism of Betaxolol can be decreased when combined with Ziprasidone. The risk or severity of adverse effects can be increased when Betaxolol is combined with Methazolamide. The risk or severity of adverse effects can be increased when Betaxolol is combined with Etacrynic acid. Rofecoxib may decrease the antihypertensive activities of Betaxolol. The metabolism of Enasidenib can be decreased when combined with Betaxolol. The metabolism of Betaxolol can be decreased when combined with Mexiletine. Naproxen may decrease the antihypertensive activities of Betaxolol. The risk or severity of adverse effects can be increased when Betaxolol is combined with Carteolol. The metabolism of Mesoridazine can be decreased when combined with Betaxolol. The metabolism of Dolasetron can be decreased when combined with Betaxolol. Ginkgo biloba may increase the bradycardic activities of Betaxolol. The metabolism of Ranitidine can be decreased when combined with Betaxolol. Betaxolol may increase the hypotensive activities of Rescinnamine. Diflunisal may decrease the antihypertensive activities of Betaxolol. Betaxolol may decrease the bronchodilatory activities of Levosalbutamol. Betaxolol may increase the hypotensive activities of Tibolone. The metabolism of Betaxolol can be decreased when combined with Indinavir. Etanercept may decrease the antihypertensive activities of Betaxolol. The risk or severity of adverse effects can be increased when Betaxolol is combined with Mannitol. Phenelzine may increase the hypotensive activities of Betaxolol. Betaxolol may increase the hypotensive activities of Saprisartan. Hydracarbazine may increase the hypotensive activities of Betaxolol. The risk or severity of adverse effects can be increased when Betaxolol is combined with Nadolol. The therapeutic efficacy of Codeine can be decreased when used in combination with Betaxolol. The metabolism of Cinnarizine can be decreased when combined with Betaxolol. Betaxolol may increase the hypotensive activities of Cicletanine. Betaxolol may increase the bradycardic activities of Crizotinib. The metabolism of Betaxolol can be decreased when combined with Tipranavir. The metabolism of Betaxolol can be decreased when combined with Theophylline. Flurbiprofen may decrease the antihypertensive activities of Betaxolol. The risk or severity of adverse effects can be increased when Betaxolol is combined with Metolazone. Ruxolitinib may increase the bradycardic activities of Betaxolol. The risk or severity of adverse effects can be increased when Thalidomide is combined with Betaxolol. Suprofen may decrease the antihypertensive activities of Betaxolol. The risk or severity of adverse effects can be increased when Betaxolol is combined with Minoxidil. Lofexidine may increase the atrioventricular blocking (AV block) activities of Betaxolol. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Betaxolol. Indobufen may decrease the antihypertensive activities of Betaxolol. Isoflurophate may increase the bradycardic activities of Betaxolol. The therapeutic efficacy of Tramadol can be decreased when used in combination with Betaxolol. Mefenamic acid may decrease the antihypertensive activities of Betaxolol. The metabolism of Ondansetron can be decreased when combined with Betaxolol. The metabolism of Mirabegron can be decreased when combined with Betaxolol. The risk or severity of adverse effects can be increased when Betaxolol is combined with Chlorothiazide. Olsalazine may decrease the antihypertensive activities of Betaxolol. The risk or severity of adverse effects can be increased when Tolcapone is combined with Betaxolol. The metabolism of Betaxolol can be decreased when combined with Dosulepin. Thioproperazine may increase the hypotensive activities of Betaxolol. The metabolism of Oxymorphone can be decreased when combined with Betaxolol. The metabolism of Phenacetin can be decreased when combined with Betaxolol. The metabolism of Tegaserod can be decreased when combined with Betaxolol. The risk or severity of adverse effects can be increased when Betaxolol is combined with Enalapril. The risk or severity of adverse effects can be increased when Betaxolol is combined with Azilsartan medoxomil. Betaxolol may decrease the bronchodilatory activities of Bambuterol. The risk or severity of adverse effects can be increased when Desflurane is combined with Betaxolol. The metabolism of Tesmilifene can be decreased when combined with Betaxolol. Dexmedetomidine may increase the atrioventricular blocking (AV block) activities of Betaxolol. Rilmenidine may increase the hypotensive activities of Betaxolol. Betaxolol may increase the bradycardic activities of Poractant alfa. Aceprometazine may increase the hypotensive activities of Betaxolol. The serum concentration of Betaxolol can be decreased when it is combined with Rifampicin. Balsalazide may decrease the antihypertensive activities of Betaxolol. The risk or severity of adverse effects can be increased when Betaxolol is combined with Amlodipine. Nafamostat may decrease the antihypertensive activities of Betaxolol. The risk or severity of adverse effects can be increased when Clofarabine is combined with Betaxolol. Betaxolol may increase the hypotensive activities of Treprostinil. Betaxolol may increase the orthostatic hypotensive activities of Terazosin. Thiopental may increase the hypotensive activities of Betaxolol. 4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Betaxolol. The risk or severity of adverse effects can be increased when Betaxolol is combined with GTS-21. Safrazine may increase the hypotensive activities of Betaxolol. Tenoxicam may decrease the antihypertensive activities of Betaxolol. E-6201 may decrease the antihypertensive activities of Betaxolol. The metabolism of Acetaminophen can be decreased when combined with Betaxolol. The risk or severity of adverse effects can be increased when Betaxolol is combined with Pindolol. The metabolism of Prochlorperazine can be decreased when combined with Betaxolol. The metabolism of Betaxolol can be decreased when combined with Ticlopidine. The metabolism of Mirtazapine can be decreased when combined with Betaxolol. The risk or severity of adverse effects can be increased when Betaxolol is combined with Atenolol. The metabolism of Halofantrine can be decreased when combined with Betaxolol. Betaxolol may increase the vasoconstricting activities of Ergoloid mesylate. Naphazoline may increase the atrioventricular blocking (AV block) activities of Betaxolol. The risk or severity of adverse effects can be increased when Betaxolol is combined with Spironolactone. The metabolism of Mequitazine can be decreased when combined with Betaxolol. The metabolism of Betaxolol can be decreased when combined with Clobazam. Guanabenz may increase the atrioventricular blocking (AV block) activities of Betaxolol. Agmatine may increase the atrioventricular blocking (AV block) activities of Betaxolol. Propacetamol may decrease the antihypertensive activities of Betaxolol. Betaxolol may increase the bradycardic activities of Calfactant. Triptolide may decrease the antihypertensive activities of Betaxolol. Methylphenidate may decrease the antihypertensive activities of Betaxolol. Betaxolol may increase the bradycardic activities of Beractant. Zomepirac may decrease the antihypertensive activities of Betaxolol. Betaxolol may increase the hypoglycemic activities of Glimepiride. Betaxolol may increase the hypotensive activities of Talinolol. Methylphenobarbital may increase the hypotensive activities of Betaxolol. The risk or severity of adverse effects can be increased when Betaxolol is combined with Metipranolol. The metabolism of Buspirone can be decreased when combined with Betaxolol. The risk or severity of adverse effects can be increased when Betaxolol is combined with Cilazapril. Betaxolol may increase the hypotensive activities of Fenoldopam. The metabolism of Benzyl alcohol can be decreased when combined with Betaxolol. The metabolism of Eletriptan can be decreased when combined with Betaxolol. Betaxolol may increase the hypoglycemic activities of Gliclazide. Furazolidone may increase the hypotensive activities of Betaxolol. The metabolism of Vortioxetine can be decreased when combined with Betaxolol. The metabolism of Moclobemide can be decreased when combined with Betaxolol. Betaxolol may increase the orthostatic hypotensive activities of Bucindolol. The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Betaxolol. The risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Betaxolol. The metabolism of Astemizole can be decreased when combined with Betaxolol. Betaxolol may increase the hypotensive activities of Cafedrine. Galantamine may increase the bradycardic activities of Betaxolol. The metabolism of Brompheniramine can be decreased when combined with Betaxolol. The risk or severity of adverse effects can be increased when Amphotericin B is combined with Betaxolol. Tiaprofenic acid may decrease the antihypertensive activities of Betaxolol. The serum concentration of Betaxolol can be increased when it is combined with Desvenlafaxine. The metabolism of Betaxolol can be decreased when combined with Terbinafine.